てんかんの擁護者は、カナダで高価な新薬Xcopriの公開報道を推進しています。 Epilepsy advocates push for public coverage of costly new drug Xcopri in Canada.

の患者や支持者は2023年にカナダで承認された新しい抗発作薬であるXcopriの公的報道を促しています Epilepsy patients and advocates are pushing for public coverage of Xcopri, a new anti-seizure drug approved in Canada in 2023. この医薬品は,また,セノバティという名で知られるが,発作を軽減し,患者生活の質を向上させる,有望な成果を生んだ. The medication, also known as cenobamate, has shown promising results in reducing seizures and improving patients' quality of life. 薬の利点にもかかわらず,Xcopriはサスカチュワン州とオンタリオ州の州薬計画では対象にならず,患者は年間3,200ドルまで支払うことになる. Despite its benefits, Xcopri is not covered under provincial drug plans in Saskatchewan and Ontario, leaving patients to pay up to $3,200 annually. 支持者はこの薬が他の薬よりも有効であると主張し,地方政府が保険の適用を再検討することを願っている. Advocates argue that the drug offers better efficacy compared to other medications and hope provincial governments will reconsider coverage.